Creative Planning Has $30.14 Million Stake in Eli Lilly and Company (NYSE:LLY)

Creative Planning grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.5% in the third quarter, HoldingsChannel.com reports. The fund owned 130,446 shares of the company’s stock after acquiring an additional 11,318 shares during the quarter. Creative Planning’s holdings in Eli Lilly and were worth $30,140,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Legacy Bridge LLC grew its holdings in Eli Lilly and by 69.2% during the 3rd quarter. Legacy Bridge LLC now owns 110 shares of the company’s stock worth $25,000 after acquiring an additional 45 shares during the period. Penserra Capital Management LLC bought a new position in shares of Eli Lilly and during the 2nd quarter worth about $33,000. Financial Insights Inc. bought a new position in shares of Eli Lilly and during the 2nd quarter worth about $36,000. Regency Capital Management Inc. DE bought a new position in Eli Lilly and in the 3rd quarter valued at about $39,000. Finally, Itau Unibanco Holding S.A. bought a new position in Eli Lilly and in the 2nd quarter valued at about $49,000. Hedge funds and other institutional investors own 81.79% of the company’s stock.

LLY stock opened at $249.52 on Friday. The firm has a 50 day moving average of $260.85 and a 200 day moving average of $250.57. The stock has a market capitalization of $238.69 billion, a PE ratio of 38.06, a price-to-earnings-growth ratio of 1.91 and a beta of 0.36. The company has a quick ratio of 1.02, a current ratio of 1.30 and a debt-to-equity ratio of 1.95. Eli Lilly and Company has a 52 week low of $178.58 and a 52 week high of $283.90.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Monday, October 25th. The company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.98 by ($0.04). The firm had revenue of $6.77 billion during the quarter, compared to analyst estimates of $6.64 billion. Eli Lilly and had a net margin of 21.52% and a return on equity of 111.51%. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.54 earnings per share. On average, equities research analysts expect that Eli Lilly and Company will post 8.18 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 10th. Shareholders of record on Tuesday, February 15th will be given a $0.98 dividend. The ex-dividend date is Monday, February 14th. This represents a $3.92 dividend on an annualized basis and a yield of 1.57%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.85. Eli Lilly and’s dividend payout ratio is presently 51.83%.

Several research firms have commented on LLY. Truist Securities increased their price objective on shares of Eli Lilly and from $262.00 to $301.00 and gave the company a “buy” rating in a research note on Wednesday, November 24th. Bank of America raised their price target on shares of Eli Lilly and from $285.00 to $300.00 and gave the stock a “buy” rating in a research note on Thursday, December 16th. The Goldman Sachs Group started coverage on shares of Eli Lilly and in a research note on Friday, December 17th. They set a “neutral” rating and a $236.00 price target for the company. Sanford C. Bernstein lifted their price objective on shares of Eli Lilly and from $250.00 to $300.00 and gave the company a “market perform” rating in a research note on Monday, January 3rd. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Eli Lilly and in a research note on Thursday, December 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and presently has an average rating of “Buy” and an average price target of $287.74.

In other news, major shareholder Lilly Endowment Inc sold 3,570 shares of the stock in a transaction dated Monday, December 27th. The shares were sold at an average price of $279.53, for a total transaction of $997,922.10. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 424,939 shares of company stock worth $114,549,362 in the last ninety days. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

Further Reading: 52-Week Highs and Lows

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.